This Just In…
Two new pharmacy benefit management companies have decided to enter the market, promising to facilitate greater drug price transparency: EmsanaRx and the Mark Cuban Cost Plus Drug Company.
Pharmacy benefit managers (PBMs) work with insurance companies, pharmacies, and manufacturers to negotiate the lowest drug costs for their members. Drug Channels Institute estimates that in 2020 about 77 percent of all prescription claims ran through the top three PBMs — CVS Health, the Express Scripts business of Cigna, and the OptumRx business of UnitedHealth Group.
EmsanaRx is a nonprofit coalition of almost 40 companies planning to offer pharmacy benefit management services to employers. EnsanaRx, which includes retailers such as Walmart and Costco, is the PBM unit of the Purchaser Business Group on Health (PBGH) coalition. Emsana Health plans to serve as an “innovation studio” which will develop new products and solutions with input from PBGH’s employer members.
The goal of the Mark Cuban Cost Plus Drug Company is to sell generic drugs at a transparent, fixed rate, and to unite manufacturing, distribution, and pharmacy services under one roof. The PBM plans to be running by 2023, according to an article in the Wall Street Journal.
Copyright © 2020 Smarts Publishing
About the Author
Share This Story
Related Blogs
C&S Specialty Underwriters Joins INSURICA
INSURICA added to its capabilities with the Jan. 1 acquisition of Atlanta-based C&S Specialty Underwriters.
SECURE Act 2.0: What Employers Should Know
At the end of December 2022, the SECURE Act 2.0 cleared both houses of Congress as part of an omnibus end of year appropriation. The Act is a package of bills focused on retirement that expands on provisions from the original SECURE Act enacted in 2019.
How to Help Employees Accelerate Retirement Savings
With retirement just around the corner for many, employees are increasingly concerned about their retirement savings for several reasons, including recent economic events, personal financial issues or job changes.